VRNA

Stock Alert: Verona Pharma Loses 14%

(RTTNews) - Shares of UK-based clinical-stage biopharmaceutical company Verona Pharma plc (VRNA) are falling more than 14 percent or $1.47 in Monday's morning trade at $8.73, after recording strong gains in the previous trading session on Friday.

Verona Pharma's stock had surged on Friday following news that it raised about $200 million in an oversubscribed private placement and subscription with new as well as existing institutional and accredited investors. The company plans to initiate a phase III program of Ensifentrine in chronic obstructive pulmonary disease, dubbed ENHANCE, later this year.

Verona Pharma has traded in a range of $2.01 to $15.71 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.